Aegea Biotechnologies, Inc.
Announces the Issuance of 7 Additional Key U.S. Patents Relating to
its Core, Next Generation Nucleic Acid Clinical Diagnostic
Technologies and COVID-19 Test Development
NEW YORK, NY and SAN DIEGO, CA -- May 18, 2020 -- InvestorsHub
NewsWire -- Aegea Biotechnologies, Inc. ( “Aegea”) (
www.aegeabiotech.com), a biotechnology company focusing on the
development and commercialization of next generation nucleic acid
clinical diagnostic technologies, announces the issuance of 7
additional key US patents related to its core next generation
nucleic acid clinical diagnostic technologies, including
applications related to COVID-19 diagnostic testing under the
collaboration agreement with Tauriga Sciences, Inc. (OTCQB:
TAUG) (“Tauriga”).
The collection of recently issued, key US patents include U.S.
Patent 10,174,352 entitled METHODS FOR AMPLIFICATION OF NUCLEIC
ACIDS ON SOLID SUPPORT, U.S. Patents 10,081,825 and 10,590,453,
entitled METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS UTILIZING A
CIRCULARIZED TEMPLATE PREPARED FROM A TARGET NUCLEIC ACID, U.S.
Patent 10,066,262, entitled METHODS FOR AMPLIFICATION OF NUCLEIC
ACIDS UTILIZING HARIPIN LOOP OR DUPLEX PRIMERS, U.S. Patent
10,202,629, entitled METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS
UTILIZING CLAMP OLIGONUCLEOTIDES, U.S. Patent 10,072,290, entitled
METHODS FOR AMPLIFYING FRAGMENTED TARGET NUCLEIC ACIDS UTILIZING AN
ASSEMBLER SEQUENCE, U.S. Patent 10,179,931, entitled METHODS FOR
IMMOBILIZING TARGET NUCLEIC ACIDS UTILIZING COMBINATORIAL CAPTURE
PROBES. These patents add to an already existing patent estate that
includes US Patent 9,834,817, entitled METHODS FOR DETECTING
NUCLEIC ACID SEQUENCE VARIANTS, as well as others.
In total, Aegea Biotechnologies, Inc. has obtained 10 issued
U.S. patents and 33 foreign equivalents. The foreign jurisdictions
include Europe, China, Japan, South Korea, and Canada.
Collectively, these patents are directed to a broad array of
enabling next generation nucleic acid technology as well as
molecular diagnostic testing technologies that include nucleic acid
PCR and isothermal amplification, the specific capture of nucleic
acid fragments of interest, the use of fragmented targets, and
methods for ultra-high sensitive detection of genetic alterations
of interest.
“We are very pleased by the issuance of these additional Aegea
patents and expect many more patent allowances both in the U.S. and
worldwide,” said Lyle Arnold, Ph.D., Aegea’s President and CEO.
“Our goal is to leverage Aegea’s patented technologies to advance
biotechnology and to aid in improving human health, particularly in
the area of clinical diagnostics. In today’s environment, we are
focusing on bringing additional options for rapidly and precisely
detecting COVID-19.”
Tauriga’s CEO, Mr. Seth Shaw, states, “Several of Aegea’s
patented, cutting edge technologies are being applied to develop
precise COVID-19 tests that are both affordable and accessible.
Tauriga is enthusiastic about the progress being realized, with
respect to its Collaboration Agreement with Aegea.”
ABOUT AEGEA BIOTECHNOLOGIES, INC.
Aegea Biotechnologies, Inc., located in San Diego, California,
is a biotechnology company focusing on the development and
commercialization of next generation nucleic acid technologies. A
primary focus for the company is nucleic acid technology
innovations that embrace molecular diagnostic assays, qPCR
technologies, sequencing methods including both Sanger and NGS, and
rapid point-of-care COVID-19 testing.
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The company
manufactures and distributes several proprietary retail products
and product lines, mainly focused on the Cannabidiol (“CBD”) and
Cannabigerol (“CBG”) Edibles market segment. The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit our
corporate website, for additional information, as well as
inquiries, at www.tauriga.com
Complimentary to the Company’s retail business, are its two
ongoing biotechnology initiatives. The first one relates to
the development of a Pharmaceutical grade version of Tauri-Gum™,
for nausea regulation (specifically designed to help patients that
are subjected to ongoing chemotherapy treatment). On March 18,
2020, the Company announced that it filed a provisional U.S. patent
application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled
“MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT”. The second one relates to a collaboration agreement
with Aegea Biotechnologies Inc. for the co-development of a rapid,
multiplexed, Novel Coronavirus (COVID-19) test with superior
sensitivity and selectivity.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the Company
operates a full time E-Commerce fulfillment center located in
LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward-looking statements due to known and
unknown risks and uncertainties, such as are not guarantees of
general economic and business conditions, the ability to
successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
CONTACT INFORMATION:
TAURIGA SCIENCES, INC.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
AEGEA BIOTECHNOLOGIES, INC.
Stella M. Sung, Ph.D.
Chief Business Officer
Email: ssung@aegeabiotech.com
Corp. Website: www.aegeabiotech.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2024 to May 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From May 2023 to May 2024